ONL Therapeutics to Present at the XXVth Biennial Meeting
Oral presentation will review the scientific rationale for Fas receptor inhibition, a unique mechanism-of-action, in the treatment of patients with......
ONL Therapeutics to Present at 2023 BIO CEO & Investor
ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for......
